Navigation Links
Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
Date:10/27/2008

$0.15 (calculated based on 22,304,000 shares) in the second quarter of fiscal 2009, compared to $0.13 per share (calculated based on 22,110,000 shares) for the same period last year.

Six Month Results: For the six-month period ended September 30, 2008, Abaxis reported revenues of $52.3 million, as compared with revenues of $48.1 million for the comparable period last year, an increase of 9 percent. Instrument, reagent disc and hematology reagent revenues increased by an aggregate of $4.5 million, or 10 percent, for the six-month period ended September 30, 2008 over the same period last year. The company reported net income of $6.1 million, compared to $6.0 million for the same period last year. The company's effective tax rate in the six months ended September 30, 2008 was 37 percent, compared to 38 percent for the same period last year. The company reported diluted net income per share of $0.27 (calculated based on 22,363,000 shares) in the six months ended September 30, 2008, compared to $0.27 per share (calculated based on 22,103,000 shares) for the same period last year.

Other Reported Financial Information: Reagent disc and hematology reagent revenues for the second quarter of fiscal 2009 were $18.7 million, up 19 percent over the $15.7 million reported in the same period last year. During the quarter, the company sold a total of 1,437,000 million units of medical and veterinary reagent discs, an increase of 16 percent compared to a total of 1,244,000 million units of medical and veterinary reagent discs sold during the same period last year. Medical sales in North America, excluding sales to the U.S. government, during the second quarter of fiscal 2009 were $4.5 million, an increase of 12 percent over last year's comparable quarter. Total sales in the medical market for the second quarter of fiscal 2009 were $6.0 million, an increase of 7 percent over last year's comparable quarter. Total sales in the veterinary market for the second quarter of
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Abaxis, Inc. to Present at the Sidoti & Companys Seventh Annual West Coast Emerging Growth Institutional Investor Forum
2. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2009
3. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
4. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
5. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
6. Trubion Reports Re-treatment Results Following Phase 1/2a and Phase 2b Studies Evaluating TRU-015 for Rheumatoid Arthritis
7. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
8. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
9. Anadys Pharmaceuticals Reports Third Quarter 2008 Financial Results and Highlights
10. Aware, Inc. Reports Third Quarter 2008 Financial Results
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... HealthTronics, Inc ., a leading ... and services, announced that a poster related to ... external beam radiotherapy (EBRT) is being presented at ... (MAAUA) Annual Meeting in Baltimore, Maryland September 18-21, ... and External Beam Radiation as Treatments for Localized ...
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
(Date:9/18/2014)... Station, Texas (PRWEB) September 18, 2014 ... System Chancellor John Sharp, Texas A&M Health Science ... the U.S. Department of Health and Human Services ... today dedicated a national pandemic influenza vaccine manufacturing ... serve as an anchor for the Texas A&M ...
(Date:9/18/2014)... -- Research and Markets has announced ... Report 2014" report to their offering. ... is a professional and in-depth study on the ... The report provides a basic overview of ... chain structure. The N-acetylcysteine market analysis is provided ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global N-acetylcysteine Industry Report 2014 2
... Maxygen, Inc. (Nasdaq: MAXY ) that it has ... also known as R7025.,MAXY-alpha is a novel interferon-alpha for ... and is licensed to Roche. Preliminary observations from ... the pharmacodynamic and pharmacokinetic effects of,MAXY-alpha occurred in the ...
... ITMN ) today announced the pricing of its ... stock at a price to the,public of $19.50 per ... purchase up to an additional 525,000 shares of common,stock. ... sold by InterMune. Goldman, Sachs & Co. is ...
... YORK, Sept. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... to,the Company,s Board of Directors. Mr. Tarnok, 53, ... with extensive pharmaceutical industry experience in a wide,range of ... career at,Pfizer Inc., which he joined in 1989 as ...
Cached Biology Technology:Maxygen Announces Hold on MAXY-alpha Development Program 2Maxygen Announces Hold on MAXY-alpha Development Program 3InterMune Announces Pricing of $68 Million Public Offering of Common Stock 2Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors 2
(Date:9/18/2014)... and nitrogen comprise all spheres of our planet. ... caused imbalances and perturbations that resulted in increases ... result in climate changes which influence the complex ... atmosphere. Understanding these feedback mechanisms has become an ... during the past three decades. , In parallel, ...
(Date:9/18/2014)... that when people are too stressed they are often ... Brain Mind Institute (BMI) at EPFL have just highlighted ... chronic stress and the loss of social skills and ... a synaptic regulatory molecule in the brain. This was ... . , Carmen Sandi,s team went to look ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):Greenhouse gas research enters a new era 2How stress tears us apart 2Transparent larvae hide opaque eyes behind reflections 2
... chronic stress day after day can produce wear and tear ... detrimental effect on learning and emotion. However, acute stress ... memory. Researchers at the University at Buffalo have shown, ... stress can produce a beneficial effect on learning and memory, ...
... and their colleagues have identified the gene that is mutated ... paraganglioma (PGL). The gene, called hSDH5, is required for activation ... the chemical reactions that take place within cells to convert ... in the journal Science , to be released online ...
... , , , ... recent analysis of the automated optical inspection (AOI) equipment market, ... & Sullivan Award for Product Innovation of the Year for ... system combines high-speed inspection with superior performance, accuracy, quality, and ...
Cached Biology News:Short stressful events may improve working memory 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 2Scientists discover gene mutation responsible for hereditary neuroendocrine tumor 3Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 2Frost & Sullivan Recognizes MIRTEC With the 2009 Award for Automated Optical Inspection Product Innovation of the Year 3
... The EC570-90 is a compact, lightweight, high ... 500 volts or 2500 milliamps. It is an ... RNA submarine gels. It is also ideal for ... time can be set to automatically end a ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
QCPN...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: